Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update

Immunic, Inc. (Nasdaq: IMUX) has scheduled a release of its financial results for the fourth quarter and year ended December 31, 2022, on February 23, 2023, before U.S. market opening.

Rhea-AI Summary

Immunic, Inc. (Nasdaq: IMUX) has scheduled a release of its financial results for the fourth quarter and year ended December 31, 2022, on February 23, 2023, before U.S. market opening. A webcast will follow at 8:00 am ET, providing corporate updates. The company is advancing its pipeline of selective oral immunology therapies aimed at chronic inflammatory and autoimmune diseases. Key products include vidofludimus calcium (IMU-838) for multiple sclerosis, IMU-935 for psoriasis and prostate cancer, and IMU-856 focusing on bowel barrier restoration. For more details, visit Immunic's official website.

Positive

• Scheduled webcast for February 23, 2023, to discuss financial results and corporate updates.
• Pipeline includes three targeted therapies with specific indications in multiple sclerosis, psoriasis, and bowel diseases.

Negative

• None.

Argus Session date unavailable

-6.60% session move Open Argus

Details

News Market Reaction – IMUX

The recorded move for IMUX in the trading session of this news was -6.60%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Webcast to be Held at 8:00 am ET on February 23, 2023 –

NEW YORK, Feb. 16, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the fourth quarter and year ended December 31, 2022, including a corporate update, on Thursday, February 23, 2023, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.

To participate in the webcast, please register in advance at: https://imux.zoom.us/webinar/register/WN_Gfg-b_qaSWugtw_SM5Gt-A or on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.

An archived replay of the webcast will be available approximately one hour after completion on Immunic's website at: ir.imux.com/events-and-presentations.

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis. IMU-935, a selective inverse agonist of the transcription factor RORγ/RORγt, is targeted for development in psoriasis, and castration-resistant prostate cancer. IMU-856, which targets the restoration of the intestinal barrier function and regeneration of bowel epithelium, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash, expected timing and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's three development programs and the targeted diseases; the potential for Immunic's development programs to safely and effectively target diseases; preclinical and clinical data for Immunic's development programs; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the Ukraine – Russia conflict on clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on February 24, 2022, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com

US Media Contact
KOGS Communication
Edna Kaplan
+1 617 974 8659
kaplan@kogspr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-inc-to-announce-financial-results-for-the-year-ended-december-31-2022-and-provide-corporate-update-301748502.html

SOURCE Immunic, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Immunic announce its financial results for the year ended December 31, 2022?

Immunic will announce its financial results on February 23, 2023.

What is the purpose of Immunic's upcoming webcast?

The webcast will provide financial results and corporate updates.

What therapies is Immunic developing?

Immunic is developing vidofludimus calcium (IMU-838), IMU-935, and IMU-856 for various autoimmune diseases.